KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$14.47 USD
-0.92 (-5.98%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $14.49 +0.02 (0.14%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
KalVista Pharmaceuticals, Inc. [KALV]
Reports for Purchase
Showing records 41 - 60 ( 106 total )
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
On-Demand HAE Treatment (KVD900) Hits a Bullseye. Increasing PT to $55
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
KOL Feedback Affirms KVD900 Merit in HAE Attacks; PT to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Quick Takeaways from Our Recent Call with Management
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Two-Pronged Strategy for HAE Advances Forward, On-Demand Data Expected 1Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY 2Q21 Earnings Update - Phase 2 HAE Data Expected in 1Q21
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
KVD824 Visibility Fuels Impetus for Emerging Oral HAE Franchise; KVD900 Phase 2 Data Expected YE20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Update Highlights Potential To Become Leading HAE Player. Reiterate Buy.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Register For Week-1 of Our Management Talk Series With IVA, RAPT, KALV - AGTC
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Fiscal Quarter Comes to a Close; With Approaching KVD900 HAE Data Expected 4Q20; Reit Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Next Week We''ll Kick Off Our Management Talk Series
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY 1Q21 Earnings Update - Two Major Value-Driving Catalysts During 4Q20
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY2020 Update - Timing of KVD900 and KVD824 Data Reaffirmed for 2H20
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Oral Kallikrein Inhibitor Progress on Horizon; On-Demand Phase 2 Data Anticipated 2H20
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department